C4 Therapeutics Ownership 2024 | Who Owns C4 Therapeutics Now?
Institutional Ownership
87.81%
Insider Ownership
11.65%
Retail Ownership
0.54%
Institutional Holders
109.00
C4 Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 10.00% | 11.52% | 6,880,527 | 3,245,865 | 89.30% | 31,788,035 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 7.09% | 0.30% | 4,878,000 | - | - | 22,536,360 | Jun 30, 2024 |
| WASATCH ADVISORS LP | 7.04% | 0.12% | 4,847,150 | 518,671 | 11.98% | 22,393,833 | Jun 30, 2024 |
| BLACKROCK INC. | 6.61% | 0.00% | 4,551,510 | 3,646,504 | 402.93% | 21,027,977 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.89% | 1.65% | 4,051,996 | 1,593,000 | 64.78% | 18,720,222 | Jun 30, 2024 |
| VANGUARD GROUP INC | 5.17% | 0.00% | 3,556,699 | 636,671 | 21.80% | 16,431,949 | Jun 30, 2024 |
| COMMODORE CAPITAL LP | 4.96% | 1.08% | 3,410,384 | - | - | 15,755,974 | Jun 30, 2024 |
| STATE STREET CORP | 4.35% | 0.00% | 2,994,948 | -4,158,332 | -58.13% | 13,836,660,000 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 2.81% | 0.02% | 1,936,139 | -499,241 | -20.50% | 8,944,962 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 2.57% | 0.00% | 1,768,499 | -86,659 | -4.67% | 8,170,466 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 2.20% | 0.14% | 1,513,058 | 1,513,058 | 100.00% | 6,990,328 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.10% | 1.57% | 1,442,841 | 6,910 | 0.48% | 6,665,925 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.98% | 0.00% | 1,362,216 | 851,901 | 166.94% | 6,294,135 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.90% | 0.01% | 1,307,733 | 135,893 | 11.60% | 6,041,726 | Jun 30, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 1.86% | 0.61% | 1,276,574 | - | - | 5,897,772 | Jun 30, 2024 |
| ARROWMARK COLORADO HOLDINGS LLC | 1.81% | 0.07% | 1,244,358 | -47,581 | -3.68% | 5,748,934 | Jun 30, 2024 |
| MORGAN STANLEY | 1.65% | 0.00% | 1,137,938 | 623,755 | 121.31% | 5,257,274 | Jun 30, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 1.62% | 0.56% | 1,111,910 | -30,300 | -2.65% | 5,137,024 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 1.07% | 0.00% | 737,835 | -543,407 | -42.41% | 3,408,798 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.90% | 0.00% | 619,112 | -12,979 | -2.05% | 2,860,297 | Jun 30, 2024 |
C4 Therapeutics's largest institutional shareholder is LYNX1 CAPITAL MANAGEMENT LP, holding 10.00% of the company's total share outstanding, currently valued at $31.79M. The top 10 institutional shareholders own together 56.50% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 10.00% | 11.52% | 6,880,527 | 3,245,865 | 89.30% | 31,788,035 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.89% | 1.65% | 4,051,996 | 1,593,000 | 64.78% | 18,720,222 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.10% | 1.57% | 1,442,841 | 6,910 | 0.48% | 6,665,925 | Jun 30, 2024 |
| COMMODORE CAPITAL LP | 4.96% | 1.08% | 3,410,384 | - | - | 15,755,974 | Jun 30, 2024 |
| TCG CROSSOVER MANAGEMENT, LLC | 1.86% | 0.61% | 1,276,574 | - | - | 5,897,772 | Jun 30, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 1.62% | 0.56% | 1,111,910 | -30,300 | -2.65% | 5,137,024 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 7.09% | 0.30% | 4,878,000 | - | - | 22,536,360 | Jun 30, 2024 |
| ATOM INVESTORS LP | 0.48% | 0.15% | 332,620 | 16,374 | 5.18% | 1,536,704 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 2.20% | 0.14% | 1,513,058 | 1,513,058 | 100.00% | 6,990,328 | Jun 30, 2024 |
| WASATCH ADVISORS LP | 7.04% | 0.12% | 4,847,150 | 518,671 | 11.98% | 22,393,833 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.29% | 0.09% | 200,000 | 200,000 | 100.00% | 924,000 | Jun 30, 2024 |
| CORTON CAPITAL INC. | 0.05% | 0.08% | 31,959 | 31,959 | 100.00% | 147,651 | Jun 30, 2024 |
| ARROWMARK COLORADO HOLDINGS LLC | 1.81% | 0.07% | 1,244,358 | -47,581 | -3.68% | 5,748,934 | Jun 30, 2024 |
| HUSSMAN STRATEGIC ADVISORS, INC. | 0.06% | 0.05% | 42,000 | 42,000 | 100.00% | 194,040 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.08% | 0.05% | 57,528 | 57,528 | 100.00% | 265,779 | Jun 30, 2024 |
| ARETE WEALTH ADVISORS, LLC | 0.16% | 0.04% | 111,300 | 26,100 | 30.63% | 514,000 | Jun 30, 2024 |
| HENNION & WALSH ASSET MANAGEMENT, INC. | 0.21% | 0.03% | 142,832 | 142,832 | 100.00% | 659,884 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.32% | 0.02% | 223,200 | 106,693 | 91.58% | 1,031,184 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.04% | 0.02% | 27,136 | 27,136 | 100.00% | 125,368 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.82% | 0.02% | 560,959 | -203,903 | -26.66% | 2,591,633 | Jun 30, 2024 |
The largest C4 Therapeutics shareholder by % of total assets is LYNX1 CAPITAL MANAGEMENT LP. The company owns 6.88M shares of C4 Therapeutics (CCCC), representing 11.52% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 6.61% | 0.00% | 4,551,510 | 3,646,504 | 402.93% | 21,027,977 | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 10.00% | 11.52% | 6,880,527 | 3,245,865 | 89.30% | 31,788,035 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.89% | 1.65% | 4,051,996 | 1,593,000 | 64.78% | 18,720,222 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 2.20% | 0.14% | 1,513,058 | 1,513,058 | 100.00% | 6,990,328 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.98% | 0.00% | 1,362,216 | 851,901 | 166.94% | 6,294,135 | Jun 30, 2024 |
| VANGUARD GROUP INC | 5.17% | 0.00% | 3,556,699 | 636,671 | 21.80% | 16,431,949 | Jun 30, 2024 |
| MORGAN STANLEY | 1.65% | 0.00% | 1,137,938 | 623,755 | 121.31% | 5,257,274 | Jun 30, 2024 |
| WASATCH ADVISORS LP | 7.04% | 0.12% | 4,847,150 | 518,671 | 11.98% | 22,393,833 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.63% | 0.00% | 431,013 | 431,013 | 100.00% | 1,991,280 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.59% | 0.00% | 405,885 | 405,885 | 100.00% | 1,875,189 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.71% | 0.00% | 488,958 | 221,529 | 82.84% | 2,258,986 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.29% | 0.09% | 200,000 | 200,000 | 100.00% | 924,000 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.28% | 0.00% | 190,761 | 190,761 | 100.00% | 881,318 | Jun 30, 2024 |
| CAPITAL FUND MANAGEMENT S.A. | 0.32% | 0.00% | 220,517 | 143,726 | 187.17% | 1,018,788 | Jun 30, 2024 |
| HENNION & WALSH ASSET MANAGEMENT, INC. | 0.21% | 0.03% | 142,832 | 142,832 | 100.00% | 659,884 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.90% | 0.01% | 1,307,733 | 135,893 | 11.60% | 6,041,726 | Jun 30, 2024 |
| BARCLAYS PLC | 0.26% | 0.00% | 175,911 | 122,818 | 231.33% | 812,000 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.32% | 0.02% | 223,200 | 106,693 | 91.58% | 1,031,184 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.16% | 0.00% | 113,436 | 91,443 | 415.78% | 524,000 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.13% | 0.00% | 90,621 | 88,830 | 4959.80% | 418,660 | Jun 30, 2024 |
As of Jun 30 2024, C4 Therapeutics's largest institutional buyer is BLACKROCK INC.. The company purchased 3.65M stocks of CCCC, valued at $21.03M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 4.35% | 0.00% | 2,994,948 | -4,158,332 | -58.13% | 13,836,660,000 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.09% | - | 62,307 | -2,053,170 | -97.05% | 288,000 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.27% | 0.00% | 185,738 | -647,943 | -77.72% | 858,110 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.40% | 0.00% | 278,580 | -627,892 | -69.27% | 1,287,037 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 1.07% | 0.00% | 737,835 | -543,407 | -42.41% | 3,408,798 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -535,342 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 2.81% | 0.02% | 1,936,139 | -499,241 | -20.50% | 8,944,962 | Jun 30, 2024 |
| UBS GROUP AG | 0.59% | 0.00% | 404,118 | -292,559 | -41.99% | 1,867,025 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.82% | 0.02% | 560,959 | -203,903 | -26.66% | 2,591,633 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -174,356 | -100.00% | - | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.34% | 0.00% | 235,200 | -170,600 | -42.04% | 1,086,624 | Jun 30, 2024 |
| MARSHALL WACE, LLP | - | - | - | -146,644 | -100.00% | - | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.52% | 0.00% | 356,212 | -140,331 | -28.26% | 1,645,699 | Jun 30, 2024 |
| MAN GROUP PLC | - | - | - | -139,900 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.38% | 0.00% | 258,426 | -129,767 | -33.43% | 1,193,928 | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | 0.17% | 0.01% | 118,473 | -106,014 | -47.23% | 547,345 | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -104,367 | -100.00% | - | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -96,964 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -92,800 | -100.00% | - | Jun 30, 2024 |
| PROFUND ADVISORS LLC | 0.05% | 0.01% | 34,149 | -92,101 | -72.95% | 157,768 | Jun 30, 2024 |
As of Jun 30 2024, C4 Therapeutics's biggest institutional seller is STATE STREET CORP. The company sold -4.16M shares of CCCC, valued at $13.84B.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2.20% | 0.14% | 1,513,058 | 1,513,058 | 100.00% | 6,990,328 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.63% | 0.00% | 431,013 | 431,013 | 100.00% | 1,991,280 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.59% | 0.00% | 405,885 | 405,885 | 100.00% | 1,875,189 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.29% | 0.09% | 200,000 | 200,000 | 100.00% | 924,000 | Jun 30, 2024 |
| HENNION & WALSH ASSET MANAGEMENT, INC. | 0.21% | 0.03% | 142,832 | 142,832 | 100.00% | 659,884 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.08% | 0.05% | 57,528 | 57,528 | 100.00% | 265,779 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.07% | 0.00% | 45,780 | 45,780 | 100.00% | 211,504 | Jun 30, 2024 |
| HUSSMAN STRATEGIC ADVISORS, INC. | 0.06% | 0.05% | 42,000 | 42,000 | 100.00% | 194,040 | Jun 30, 2024 |
| CORTON CAPITAL INC. | 0.05% | 0.08% | 31,959 | 31,959 | 100.00% | 147,651 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.05% | 0.00% | 31,543 | 31,543 | 100.00% | 146,044 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.04% | 0.00% | 29,848 | 29,848 | 100.00% | 137,898 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.03% | 0.00% | 23,700 | 23,700 | 100.00% | 109,000 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.03% | 0.00% | 22,100 | 22,100 | 100.00% | 102,102 | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | 0.03% | 0.00% | 19,735 | 19,735 | 100.00% | 91,176 | Jun 30, 2024 |
| METLIFE INVESTMENT MANAGEMENT, LLC | 0.02% | 0.00% | 15,477 | 15,477 | 100.00% | 71,504 | Jun 30, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.02% | - | 12,937 | 12,937 | 100.00% | 59,769 | Jun 30, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.02% | 0.00% | 12,025 | 12,025 | 100.00% | 55,556 | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | 0.01% | 0.00% | 10,162 | 10,162 | 100.00% | 46,948 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.01% | 0.00% | 6,993 | 6,993 | 100.00% | 32,308 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | 0.00% | 5,744 | 5,744 | 100.00% | 26,537 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.01% | - | 5,063 | 5,063 | 100.00% | 23,340 | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.01% | - | 4,248 | 4,248 | 100.00% | 19,626 | Jun 30, 2024 |
| AMALGAMATED BANK | 0.00% | 0.00% | 2,029 | 2,029 | 100.00% | 9,000 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.00% | - | 1,735 | 1,735 | 100.00% | 8,016,000 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 0.00% | - | 316 | 316 | 100.00% | 1,460,000 | Jun 30, 2024 |
| PLANNING CAPITAL MANAGEMENT CORP | 0.00% | 0.00% | 35 | 35 | 100.00% | 162 | Jun 30, 2024 |
| GRADIENT INVESTMENTS LLC | - | - | 25 | 25 | 100.00% | 116 | Jun 30, 2024 |
| ROTHSCHILD INVESTMENT LLC | - | - | 25 | 25 | 100.00% | 116 | Jun 30, 2024 |
C4 Therapeutics's largest new institutional shareholder by number of shares is ORBIMED ADVISORS LLC, purchased 1.51M shares, valued at $6.99M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -535,342 | -100.00% | - | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -174,356 | -100.00% | - | Jun 30, 2024 |
| MARSHALL WACE, LLP | - | - | - | -146,644 | -100.00% | - | Jun 30, 2024 |
| MAN GROUP PLC | - | - | - | -139,900 | -100.00% | - | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -104,367 | -100.00% | - | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -96,964 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -92,800 | -100.00% | - | Jun 30, 2024 |
| SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | - | - | - | -91,127 | -100.00% | - | Jun 30, 2024 |
| QUEST PARTNERS LLC | - | - | - | -64,001 | -100.00% | - | Jun 30, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | - | - | - | -47,449 | -100.00% | - | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | - | - | - | -41,445 | -100.00% | - | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | - | - | - | -28,590 | -100.00% | - | Jun 30, 2024 |
| WALLEYE TRADING LLC | - | - | - | -24,794 | -100.00% | - | Jun 30, 2024 |
| ROYCE & ASSOCIATES LP | - | - | - | -23,604 | -100.00% | - | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | - | - | - | -22,368 | -100.00% | - | Jun 30, 2024 |
| POLYMER CAPITAL MANAGEMENT (HK) LTD | - | - | - | -21,906 | -100.00% | - | Jun 30, 2024 |
| LMR PARTNERS LLP | - | - | - | -19,563 | -100.00% | - | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | - | - | - | -18,317 | -100.00% | - | Jun 30, 2024 |
| ENTROPY TECHNOLOGIES, LP | - | - | - | -15,391 | -100.00% | - | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -14,900 | -100.00% | - | Jun 30, 2024 |
| PRINCIPAL FINANCIAL GROUP INC | - | - | - | -13,238 | -100.00% | - | Jun 30, 2024 |
| QUANTBOT TECHNOLOGIES LP | - | - | - | -10,300 | -100.00% | - | Jun 30, 2024 |
| MACQUARIE GROUP LTD | - | - | - | -4,009 | -100.00% | - | Jun 30, 2024 |
| US BANCORP \DE\ | - | - | - | -39 | -100.00% | - | Jun 30, 2024 |
C4 Therapeutics's largest sold out institutional shareholder by shares sold is LAURION CAPITAL MANAGEMENT LP, sold -0.54M shares, valued at -, as of undefined.
C4 Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Clough Global Equity Fund | 1.43% | 88,500 | - | - | Jan 31, 2024 |
| Clough Global Opportunities Fund | 0.41% | 161,281 | - | - | Jan 31, 2024 |
| Clough Funds Trust | 0.34% | 14,000 | - | - | Jan 31, 2023 |
| WASATCH FUNDS TRUST | 0.30% | 2,816,041 | -1,870,419 | -39.91% | Mar 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.23% | 1,164,278 | -241,792 | -17.20% | Mar 31, 2024 |
| MERIDIAN FUND INC | 0.21% | 486,139 | -467,767 | -49.04% | Mar 28, 2024 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.14% | 9,815 | - | - | Sep 30, 2022 |
| VANGUARD EXPLORER FUND | 0.13% | 1,651,861 | - | - | Jan 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.13% | 24,124 | - | - | Mar 28, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.11% | 381,492 | - | - | Mar 31, 2024 |
| PRUDENTIAL SECTOR FUNDS, INC. | 0.10% | 209,981 | - | - | Feb 29, 2024 |
| BlackRock Health Sciences Trust II | 0.08% | 201,293 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 31,822 | - | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.06% | 468,657 | - | - | Mar 31, 2024 |
| Vericimetry Funds | 0.06% | 5,070 | - | - | Mar 31, 2024 |
| ROYCE MICRO-CAP TRUST, INC. | 0.05% | 23,604 | -24,531 | -50.96% | Mar 31, 2024 |
| PRUDENTIAL JENNISON BLEND FUND, INC. | 0.04% | 26,048 | - | - | Feb 29, 2024 |
| Federated Hermes MDT Series | 0.03% | 63,459 | - | - | Jan 31, 2024 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.02% | 75,400 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.02% | 49,000 | -75,000 | -60.48% | Mar 28, 2024 |
| Humankind Benefit Corp | 0.02% | 439 | - | - | Dec 31, 2023 |
| T. Rowe Price Equity Series, Inc. | 0.01% | 21,403 | - | - | Mar 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.01% | 591,714 | - | - | Mar 31, 2024 |
| Fidelity Commonwealth Trust II | 0.01% | 74,120 | 40,612 | 121.20% | Aug 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 65,317 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 6,192 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 579,281 | - | - | Feb 29, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.01% | 86,239 | - | - | Mar 31, 2024 |
| ETFis Series Trust I | 0.01% | 12,350 | - | - | Jan 31, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.01% | 41,400 | - | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.01% | 69,700 | - | - | Jan 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.01% | 649,186 | 592,949 | 1054.38% | Jan 31, 2024 |
| AIM EQUITY FUNDS (INVESCO EQUITY FUNDS) | 0.01% | 104,040 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 2,816,153 | 238,514 | 9.25% | Mar 31, 2024 |
| Harbor ETF Trust | 0.00% | 23,300 | 198 | 0.86% | Jan 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 15,612 | - | - | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 970 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 74,120 | - | - | Jan 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 105,714 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 42,325 | 41,792 | 7840.90% | Mar 31, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.00% | 27,203 | - | - | Mar 28, 2024 |
| ALPS ETF Trust | 0.00% | 30,916 | - | - | Feb 29, 2024 |
| NEUBERGER BERMAN EQUITY FUNDS | 0.00% | 23,991 | - | - | Feb 29, 2024 |
| HARBOR FUNDS | 0.00% | 54,762 | -572 | -1.03% | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 6,367 | - | - | Mar 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 95,550 | - | - | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 41,410 | 13,957 | 50.84% | Mar 31, 2024 |
| AIM COUNSELOR SERIES TRUST (INVESCO COUNSELOR SERIES TRUST) | 0.00% | 311,185 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 233,668 | -122,511 | -34.40% | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 2,962 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 13,238 | -1,515 | -10.27% | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 335,365 | - | - | Dec 31, 2023 |
| Managed Portfolio Series | 0.00% | 23,160 | - | - | Jan 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 139,285 | - | - | Jan 31, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 6,851 | - | - | Dec 31, 2023 |
| BlackRock ETF Trust | 0.00% | 610 | - | - | Jan 31, 2024 |
| Dimensional ETF Trust | 0.00% | 282,498 | 257,422 | 1026.57% | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 12,400 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 21,536 | - | - | Jan 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 16,458 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 237,802 | 8,090 | 3.52% | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 45,550 | 11,475 | 33.68% | Feb 29, 2024 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 41,400 | - | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 16,257 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 49,047 | - | - | Mar 31, 2024 |
| RBB FUND, INC. | 0.00% | 33,996 | - | - | Feb 29, 2024 |
| VANGUARD HORIZON FUNDS | 0.00% | 8,027 | - | - | Mar 31, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 6,485 | - | - | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,389 | - | - | Mar 31, 2024 |
| Trust for Advised Portfolios | 0.00% | 4,903 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,543 | 260 | 11.39% | Mar 31, 2024 |
| SPDR SERIES TRUST | 0.00% | 6,945,777 | 5,228,910 | 304.56% | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 39,029 | - | - | Feb 29, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,300 | - | - | Mar 31, 2024 |
| FLEXSHARES TRUST | 0.00% | 12,351 | - | - | Jan 31, 2024 |
| Victory Portfolios II | 0.00% | 7,482 | - | - | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 15,700 | 14,900 | 1862.50% | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 356,332 | - | - | Mar 31, 2024 |
| Forethought Variable Insurance Trust | 0.00% | 435 | - | - | Mar 28, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 387 | - | - | Dec 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 367,861 | - | - | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 460 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 152,164 | - | - | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 76,942 | 52,407 | 213.60% | Jan 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 18,639 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 169,023 | -5,160 | -2.96% | Dec 31, 2023 |
| VALIC Co I | 0.00% | 15,482 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 6,373 | 6,134 | 2566.53% | Jan 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 4,328 | - | - | Mar 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 192 | - | - | Dec 31, 2023 |
| PENN SERIES FUNDS INC | 0.00% | 1,300 | - | - | Mar 28, 2024 |
| NORTHERN FUNDS | 0.00% | 6,094 | - | - | Mar 28, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 3,528 | - | - | Mar 31, 2024 |
| J.P. Morgan Exchange-Traded Fund Trust | 0.00% | 11,213 | - | - | Jan 31, 2024 |
| MORGAN STANLEY INSTITUTIONAL FUND INC | 0.00% | 1,580 | - | - | Mar 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 25 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 20,231 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 4,379 | - | - | Jan 31, 2024 |
| HC CAPITAL TRUST | 0.00% | 585 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,683 | - | - | Feb 29, 2024 |
C4 Therapeutics's largest mutual fund holder by % of total assets is "Clough Global Equity Fund", owning 88.50K shares, compromising 1.43% of its total assets.
C4 Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 109 | -0.91% |
| 31 Mar, 24 | 110 | 17.02% |
| 31 Dec, 23 | 94 | 16.05% |
| 30 Sep, 23 | 81 | -16.49% |
| 30 Jun, 23 | 97 | -17.09% |
| 31 Mar, 23 | 117 | 2.63% |
| 31 Dec, 22 | 114 | 0.88% |
| 30 Sep, 22 | 113 | 0.89% |
| 30 Jun, 22 | 112 | -13.18% |
| 31 Mar, 22 | 129 | 8.40% |
| 31 Dec, 21 | 119 | 3.48% |
| 30 Sep, 21 | 115 | 5.50% |
| 30 Jun, 21 | 109 | 29.76% |
| 31 Mar, 21 | 84 | 12.00% |
| 31 Dec, 20 | 75 | - |
As of 30 Jun 24, 109 institutions are holding C4 Therapeutics's shares, representing a decrease of -0.91% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 60,425,144 | 4.24% |
| 31 Mar, 24 | 57,968,690 | 23.84% |
| 31 Dec, 23 | 46,808,581 | 35.47% |
| 30 Sep, 23 | 34,553,219 | 1.32% |
| 30 Jun, 23 | 34,104,689 | -8.54% |
| 31 Mar, 23 | 37,290,382 | -4.56% |
| 31 Dec, 22 | 39,071,538 | -0.66% |
| 30 Sep, 22 | 39,330,972 | 0.10% |
| 30 Jun, 22 | 39,290,594 | 5.55% |
| 31 Mar, 22 | 37,223,168 | 3.83% |
| 31 Dec, 21 | 35,850,680 | 3.92% |
| 30 Sep, 21 | 34,498,254 | 7.99% |
| 30 Jun, 21 | 31,945,881 | 27.28% |
| 31 Mar, 21 | 25,099,400 | 10.54% |
| 31 Dec, 20 | 22,706,751 | - |
C4 Therapeutics (CCCC) has 60.43M shares outstanding as of 30 Jun 24, up 4.24% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 87.81% | 1.22% |
| 31 Mar, 24 | 84.71% | 1.01% |
| 31 Dec, 23 | 91.39% | 1.85% |
| 30 Sep, 23 | 70.21% | 1.45% |
| 30 Jun, 23 | 69.51% | 1.20% |
| 31 Mar, 23 | 76.05% | 1.19% |
| 31 Dec, 22 | 79.79% | 1.23% |
| 30 Sep, 22 | 80.40% | 1.24% |
| 30 Jun, 22 | 80.47% | 1.37% |
| 31 Mar, 22 | 76.52% | 1.40% |
| 31 Dec, 21 | 73.93% | 1.46% |
| 30 Sep, 21 | 71.14% | 1.34% |
| 30 Jun, 21 | 72.84% | 2.15% |
| 31 Mar, 21 | 58.26% | 2.09% |
| 31 Dec, 20 | 52.73% | - |
As of 30 Jun 24, C4 Therapeutics is held by 87.81% institutional shareholders, representing a 1.22% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 63 | -5.97% |
| 31 Mar, 24 | 67 | 21.82% |
| 31 Dec, 23 | 55 | 44.74% |
| 30 Sep, 23 | 38 | -25.49% |
| 30 Jun, 23 | 51 | -19.05% |
| 31 Mar, 23 | 63 | 12.50% |
| 31 Dec, 22 | 56 | -9.68% |
| 30 Sep, 22 | 62 | -4.62% |
| 30 Jun, 22 | 65 | -9.72% |
| 31 Mar, 22 | 72 | 16.13% |
| 31 Dec, 21 | 62 | -13.89% |
| 30 Sep, 21 | 72 | -10.00% |
| 30 Jun, 21 | 80 | 70.21% |
| 31 Mar, 21 | 47 | -37.33% |
| 31 Dec, 20 | 75 | - |
63 institutional shareholders have increased their position in CCCC stock as of 30 Jun 24 compared to 67 in the previous quarter (a -5.97% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 32 | 18.52% |
| 31 Mar, 24 | 27 | 8.00% |
| 31 Dec, 23 | 25 | -16.67% |
| 30 Sep, 23 | 30 | -16.67% |
| 30 Jun, 23 | 36 | - |
| 31 Mar, 23 | 36 | 12.50% |
| 31 Dec, 22 | 32 | - |
| 30 Sep, 22 | 32 | -3.03% |
| 30 Jun, 22 | 33 | 6.45% |
| 31 Mar, 22 | 31 | -6.06% |
| 31 Dec, 21 | 33 | 65.00% |
| 30 Sep, 21 | 20 | 53.85% |
| 30 Jun, 21 | 13 | -38.10% |
| 31 Mar, 21 | 21 | - |
| 31 Dec, 20 | - | - |
32 institutional shareholders have reduced their position in CCCC stock as of 30 Jun 24 compared to 27 in the previous quarter (a 18.52% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 109 | -0.91% | 60,425,144 | 4.24% | 87.81% | 1.22% | 63 | -5.97% | 32 | 18.52% |
| 31 Mar, 24 | 110 | 17.02% | 57,968,690 | 23.84% | 84.71% | 1.01% | 67 | 21.82% | 27 | 8.00% |
| 31 Dec, 23 | 94 | 16.05% | 46,808,581 | 35.47% | 91.39% | 1.85% | 55 | 44.74% | 25 | -16.67% |
| 30 Sep, 23 | 81 | -16.49% | 34,553,219 | 1.32% | 70.21% | 1.45% | 38 | -25.49% | 30 | -16.67% |
| 30 Jun, 23 | 97 | -17.09% | 34,104,689 | -8.54% | 69.51% | 1.20% | 51 | -19.05% | 36 | - |
| 31 Mar, 23 | 117 | 2.63% | 37,290,382 | -4.56% | 76.05% | 1.19% | 63 | 12.50% | 36 | 12.50% |
| 31 Dec, 22 | 114 | 0.88% | 39,071,538 | -0.66% | 79.79% | 1.23% | 56 | -9.68% | 32 | - |
| 30 Sep, 22 | 113 | 0.89% | 39,330,972 | 0.10% | 80.40% | 1.24% | 62 | -4.62% | 32 | -3.03% |
| 30 Jun, 22 | 112 | -13.18% | 39,290,594 | 5.55% | 80.47% | 1.37% | 65 | -9.72% | 33 | 6.45% |
| 31 Mar, 22 | 129 | 8.40% | 37,223,168 | 3.83% | 76.52% | 1.40% | 72 | 16.13% | 31 | -6.06% |
| 31 Dec, 21 | 119 | 3.48% | 35,850,680 | 3.92% | 73.93% | 1.46% | 62 | -13.89% | 33 | 65.00% |
| 30 Sep, 21 | 115 | 5.50% | 34,498,254 | 7.99% | 71.14% | 1.34% | 72 | -10.00% | 20 | 53.85% |
| 30 Jun, 21 | 109 | 29.76% | 31,945,881 | 27.28% | 72.84% | 2.15% | 80 | 70.21% | 13 | -38.10% |
| 31 Mar, 21 | 84 | 12.00% | 25,099,400 | 10.54% | 58.26% | 2.09% | 47 | -37.33% | 21 | - |
| 31 Dec, 20 | 75 | - | 22,706,751 | - | 52.73% | - | 75 | - | - | - |
C4 Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of C4 Therapeutics's stock was made by REYNO LEONARD on Jul 11 2024, selling 6,191 shares at $5.00 per share (valued at $30.95K).
C4 Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 2 | 1 | 200.00% |
| Q2 2024 | 11 | - | - |
| Q1 2024 | 27 | 14 | 192.86% |
| Q4 2023 | 4 | - | - |
| Q3 2023 | 18 | 18 | 100.00% |
| Q2 2023 | 9 | - | - |
| Q1 2023 | 25 | 16 | 156.25% |
| Q4 2022 | 5 | 2 | 250.00% |
| Q3 2022 | 6 | 3 | 200.00% |
| Q2 2022 | 16 | 12 | 133.33% |
| Q1 2022 | 19 | 10 | 190.00% |
| Q4 2021 | 11 | 12 | 91.67% |
| Q3 2021 | 9 | 43 | 20.93% |
| Q2 2021 | 20 | 7 | 285.71% |
| Q1 2021 | 11 | 6 | 183.33% |
| Q4 2020 | 29 | 40 | 72.50% |
2 total buy trades, and 1 total sell trades (buy/sell ratio of 2.00%) were made by C4 Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | 1 | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | - | 2 | - |
| Q4 2021 | - | 6 | - |
| Q3 2021 | - | 39 | - |
| Q2 2021 | - | 4 | - |
| Q1 2021 | - | - | - |
| Q4 2020 | 3 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of C4 Therapeutics's stocks.
C4 Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| NRIX | Nurix Therapeutics, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
CCCC Ownership FAQ
Who Owns C4 Therapeutics?
C4 Therapeutics is owned by institutional shareholders (87.81%), insiders (11.65%), and public (0.54%). The largest institutional shareholder of C4 Therapeutics is LYNX1 CAPITAL MANAGEMENT LP (10.00% of total shares) and the top mutual fund owner is Clough Global Equity Fund (1.43% of total shares).
Who are the major institutional shareholders of C4 Therapeutics?
C4 Therapeutics's major institutional shareholders are LYNX1 CAPITAL MANAGEMENT LP, RA CAPITAL MANAGEMENT, L.P., WASATCH ADVISORS LP, BLACKROCK INC., and SOLEUS CAPITAL MANAGEMENT, L.P.. The top five shareholders own together 36.64% of the company's share outstanding.
How many C4 Therapeutics shareholders are there?
As of Jun 2024, there are 109 institutional shareholders of C4 Therapeutics.
What percentage of C4 Therapeutics is owned by LYNX1 CAPITAL MANAGEMENT LP?
LYNX1 CAPITAL MANAGEMENT LP owns 6.88M shares of C4 Therapeutics, representing 10.00% of the company's total shares outstanding, valued at $31.79M (as of Jun 2024).
What percentage of C4 Therapeutics is owned by RA CAPITAL MANAGEMENT, L.P?
As of Jun 2024, RA CAPITAL MANAGEMENT, L.P holds 4.88M shares of C4 Therapeutics (CCCC), compromising 7.09% of the company, valued at $22.54M.
What percentage of C4 Therapeutics is owned by WASATCH ADVISORS LP?
WASATCH ADVISORS LP is the third largest holder of C4 Therapeutics. The company owns 4.85M of the company's shares outstanding (worth $22.39M).